GLP-1 and GIP are naturally occurring gut hormones that help us feel full and suppress our appetite to eat. They also interact with natural pathways that regulate blood sugar levels.

GLP-1 and GLP-1/GIP medications are typically injected subcutaneously (under the skin). They are available as pre-filled pens or syringes, and the injections are usually self-administered. Roczen will ensure you are comfortable and confident with administering the medication independently.

GLP-1 and GLP-1/GIP medications can be used to aid weight management in people with obesity who have already tried lifestyle modifications. They must be used alongside a healthy diet and increased physical activity to promote effective weight loss. They are also prescribed to improve blood sugar and weight in people with Type 2 diabetes.

More recent GLP-1s (third generation GLP-1s like Wegovy^Ⓡ) have shown to be very effective in some people. Clinical trials have demonstrated significant weight reduction, with the majority of individuals achieving over a 15% loss of their initial body weight. The GLP-1/GIP medication tirzepatide has also been demonstrated to achieve clinically significant weight loss of 20-25% within a year. It’s important to remember that different people will require different treatment options, and what works for others may not work for you.

GLP-1 and GLP-1/GIP medications alone are not usually associated with low blood sugar (also known as hypoglycaemia). However, if used in combination with other diabetes medications that can lower blood sugar (such as insulin or sulfonylureas), there can be an increased risk. Your doctor will give you advice regarding your current medications if you are prescribed a GLP-1 or GLP-1/GIP.

Generally, GLP-1s and combined GLP-1/GIPs can be prescribed to individuals with a BMI of 30 or higher, or individuals with a BMI of 27 or higher with at least one weight-related comorbidity (such as high blood pressure, Type 2 diabetes or obstructive sleep apnea). However, some conditions may mean these medications are not for everyone. On the Roczen Plus programme, a GLP-1 and GLP1/GIP suitability assessment will be conducted by our in-house team of medical doctors. 

Weight-loss results can vary among individuals, but many people start to see noticeable weight loss within the first few weeks to months of starting treatment with GLP-1s or GLP-1/GIPs. If you are prescribed a GLP-1 or GLP-1/GIP medication and you feel like you are not making progress, please speak with your doctor who will be happy to help you.

GLP-1 and GLP-1/GIP medications should not be used during pregnancy or breastfeeding, as there is limited safety data available.

GLP-1 and GIP have a few actions in the body. They lead to hormonal changes that reduce blood sugar. They also slow how quickly your stomach empties, which reduces your appetite. This leads to reduced calorie intake and weight loss over time.

GLP-1 and combined GLP-1 and GIP receptor agonists (GLP-1/GIPs) are a class of medicines used in the treatment of Type 2 diabetes and obesity. They act in a very similar way to the GLP-1 and GIP hormones, naturally found in our bodies (to increase the feeling of fullness and make us less hungry).

Some common brand names for GLP-1 medications include Wegovy^Ⓡ (semaglutide), Rybelsus^Ⓡ, (semaglutide), Ozempic^Ⓡ (semaglutide), Saxenda^Ⓡ (liraglutide), Victoza^Ⓡ (liraglutide), Byetta^Ⓡ (exenatide), Trulicity^Ⓡ (dulaglutide). GLP-1/GIP medication is sold under the brand name Mounjaro^Ⓡ.

Like any medication, GLP-1s and GLP-1/GIPs can have side effects. Common side effects may include nausea, vomiting, diarrhoea, constipation and headaches. However, these side effects are generally mild and tend to improve over time. The medication is often started at a lower dose and gradually increased over time to reduce the risk of side effects. 

There are no specific dietary restrictions while taking GLP-1 or GLP-1/GIP medications. However, it's important to follow a healthy diet as part of a lifestyle management programme in addition to the medication.

Currently, the GLP-1 approved for the treatment of obesity are liraglutide (Saxenda^Ⓡ) and semaglutide (Wegovy^Ⓡ). The GLP-1/GIP approved for treatment of obesity is tirzepatide (Mounjaro^Ⓡ). These medications are given via self-injection and are typically prescribed in higher doses compared to their doses in the management of diabetes.

The duration of treatment with GLP-1 or GLP-1/GIP can vary depending on individual needs. Most people require long-term treatment. However, the duration of treatment and continued effectiveness will be monitored by your Roczen clinician to assess the ongoing benefits and manage any potential risks.

Injectable GLP-1s and GLP-1/GIPs can be taken at any time of day. They are taken once weekly and should be taken on the same day of the week, at roughly the same time of day.